AI
ByBlackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape
Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…
Has China Now Overtaken the US at the Heart of Biotech Innovation?
Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…
Is Hong Kong Becoming Asia’s AI–Biopharma Hub?
Hong Kong is emerging as a key AI‑biopharma hub, with recent deals like Earendil Labs’ partnership with Sanofi…
Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?
Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030?
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030? Gilead Sciences executes a precision oncology…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
